PMID- 23962489
OWN - NLM
STAT- MEDLINE
DCOM- 20140117
LR  - 20151119
IS  - 1448-5028 (Print)
IS  - 1448-5028 (Linking)
VI  - 10
IP  - 5
DP  - 2013 Nov
TI  - Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual 
      health clinic.
PG  - 438-41
LID - 10.1071/SH13018 [doi]
AB  - BACKGROUND: Non-occupational HIV post-exposure prophylaxis (NPEP) is prescribed 
      following a risk exposure in an effort to reduce the risk of HIV seroconversion. 
      We aimed to describe the prescribing practices of NPEP at RPA Sexual Health in 
      Sydney, the prevalence and correlates of adverse events (AEs), and factors 
      associated with completing the 28-day course. METHODS: The study population 
      included individuals prescribed NPEP during January 2008-December 2011. 
      Correlates of AEs and course completion were assessed by logistic regression. 
      RESULTS: On 319 occasions during the study period, 282 individuals presented for 
      NPEP. Over 90% of presentations followed unprotected anal intercourse between 
      men, mostly receptive (63.6%). Tenofovir-emtricitabine-stavudine (n=149; 46.7%) 
      and tenofovir-emtricitabine (n=136; 42.6%) were most commonly prescribed. AEs 
      were reported at 101 presentations (31.7%, 95% confidence interval (CI): 
      26.6-37.1%), with nausea and lethargy/malaise being the most common. Younger age 
      (P for trend=0.032), earlier year of NPEP prescription (P for trend=0.011), being 
      prescribed a regimen other than tenofovir-emtricitabine (P=0.026), changing the 
      NPEP regimen (P<0.001) and known completion of the course (P=0.005) were 
      independently associated with AEs. The course was completed in 228 presentations 
      (71.5%, 95% CI: 66.2-76.4%). Completion was associated with reporting AEs 
      (P=0.007) and changing regimen (P=0.001). No documented NPEP failures were 
      identified, although two recipients subsequently seroconverted to HIV due to 
      ongoing high-risk behaviour. CONCLUSIONS: NPEP is appropriately targeted to the 
      highest risk HIV exposures at our clinic. Active recall may improve follow-up 
      rates in NPEP recipients.
FAU - Gulholm, Trine
AU  - Gulholm T
AD  - RPA Sexual Health, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
FAU - Jamani, Salina
AU  - Jamani S
FAU - Poynten, I Mary
AU  - Poynten IM
FAU - Templeton, David J
AU  - Templeton DJ
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Sex Health
JT  - Sexual health
JID - 101242667
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Organophosphonates)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 99YXE507IL (Tenofovir)
RN  - BO9LE4QFZF (Stavudine)
RN  - G70B4ETF4S (Emtricitabine)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Adenine/administration & dosage/analogs & derivatives
MH  - Adult
MH  - Anti-HIV Agents/*administration & dosage/adverse effects
MH  - Australia
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Emtricitabine
MH  - HIV Infections/*prevention & control
MH  - Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Organophosphonates/administration & dosage
MH  - Post-Exposure Prophylaxis/*statistics & numerical data
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Risk-Taking
MH  - Stavudine/administration & dosage
MH  - Tenofovir
EDAT- 2013/08/22 06:00
MHDA- 2014/01/18 06:00
CRDT- 2013/08/22 06:00
PHST- 2013/02/01 00:00 [received]
PHST- 2013/06/20 00:00 [accepted]
PHST- 2013/08/22 06:00 [entrez]
PHST- 2013/08/22 06:00 [pubmed]
PHST- 2014/01/18 06:00 [medline]
AID - SH13018 [pii]
AID - 10.1071/SH13018 [doi]
PST - ppublish
SO  - Sex Health. 2013 Nov;10(5):438-41. doi: 10.1071/SH13018.